



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Aripiprazole Injection

Page: 1 of 2

Effective Date: 3/4/2024

Last Review Date: 01/2024

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for aripiprazole injection products under the patient’s prescription drug benefit.

Description:

Abilify Asimtufii

Abilify Asimtufii is indicated is indicated for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults.

Abilify Maintena

Abilify Maintena is indicated for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults.

Aristada

Aristada is indicated for treatment of schizophrenia.

Aristada Initio

Aristada Initio, in combination with oral aripiprazole, is indicated for the initiation of Aristada when used for the treatment of schizophrenia in adults

Applicable Drug List:

Abilify Asimtufii
Abilify Maintena
Aristada
Aristada Initio

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- Tolerability with oral aripiprazole has been established

AND

- The requested drug is being prescribed for the treatment of schizophrenia
- OR**
- Abilify Maintena or Abilify Asimtufii is being prescribed for maintenance monotherapy treatment of bipolar I disorder



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Aripiprazole Injection	Page:	2 of 2
Effective Date:	3/4/2024	Last Review Date:	01/2024
Applies to:	<input checked="" type="checkbox"/> Illinois <input type="checkbox"/> New Jersey <input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Abilify Maintena [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; June 2020.
2. Aristada [package insert]. Waltham, MA: Alkermes, Inc.; March 2021.
3. Aristada Initio [package insert]. Waltham, MA: Alkermes, Inc.; March 2021.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed September 14, 2023.
5. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 09/14/2023).
6. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. Third Edition. Washington, DC: American Psychiatric Association; 2021. Available at: <https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841>. Accessed August 23, 2023.
7. Hirschfeld RM, Bowden CL, Gitlin MJ, et al. American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Bipolar Disorder. Second Edition. Washington DC: American Psychiatric Association; 2002. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf. Accessed August 28, 2023.
8. McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry*. 2013;52(9):976-90.
9. McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. *J Am Acad Child Adolesc Psychiatry*. 2007;46(1):107-25